A radionuclide-labeled nanomedicine for STING pathway activation- and oxygenation-augmented orthotopic cancer radioisotope-immunotherapy
Chemical Engineering Journal, ISSN: 1385-8947, Vol: 483, Page: 149223
2024
- 1Citations
- 1Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
New Cancer Data Have Been Reported by Researchers at Xiangya Hospital (A Radionuclide-labeled Nanomedicine for Sting Pathway Activation- and Oxygenation-augmented Orthotopic Cancer Radioisotope-immunotherapy)
2024 APR 05 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Data detailed on Cancer have been presented. According to news
Article Description
Current internal radioisotope therapy (RIT) struggles to achieve desirable treatment outcomes in solid tumors due to inadequate tumor-targeted delivery of radionuclides, and the hypoxic and immunosuppressive tumor microenvironment (TME). In this study, we rationally design and fabricate a radionuclide-labeled nanomedicine in which a tumor-targeting metal-phenolic network (MPN) is coated on the surface of 32 P-labeled biomineralized calcium phosphate (C-Ca 32 P) nanoparticles to realize targeted delivery of radionuclides and ABZI (a stimulator of interferon genes (STING) agonist). After internalization by tumor cells, such nanomedicine could alleviate hypoxia by oxygenation. Meanwhile, the pH-responsive decomposition of this nanomedicine triggers the liberation of radioactive 32 P, Mn 2+ and ABZI from acidic lysosomes, wherein ABZI and Mn 2+ synergistically potentiate STING signaling. Notably, the activation of STING pathway and in situ oxygenation sensitize tumor cells to 32 P-midiated internal radiation and arouse a type I interferons (IFNs)-related adaptive immune response, achieving obvious synergistic effect in eradicating orthotopic breast tumors. After combination with checkpoint blockade therapy, this nanomedicine could lead to amplified therapeutic effect and inhibition of distant tumor metastases. This study presents a promising strategy for internal radiation sensitization and immune activation, holding significant potential for enhanced radioisotope-immunotherapy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1385894724007083; http://dx.doi.org/10.1016/j.cej.2024.149223; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85183994903&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1385894724007083; https://dx.doi.org/10.1016/j.cej.2024.149223
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know